BioCardia (BCDA) Common Equity (2010 - 2026)

BioCardia (BCDA) has reported Common Equity for 16 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 243.16% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $2.7 million, a 243.16% increase from a year earlier, with the FY2025 full-year figure at $895000.0, up 6.93% from the prior year.
• Common Equity was $2.7 million for Q2 2026 at BioCardia, up from -$1.1 million in the prior quarter.
• Over five years, Common Equity peaked at $7.4 million in Q1 2022 and troughed at -$2.3 million in Q1 2024.
• A 5-year average of $1.4 million and a median of $1.3 million in 2023 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 517.12% in 2024, down 219.94% in 2024.
• Over 5 years, Common Equity stood at $4.9 million in 2022, then sank by 132.77% to -$1.6 million in 2023, then jumped by 152.21% to $837000.0 in 2024, then increased by 6.93% to $895000.0 in 2025, then surged by 201.68% to $2.7 million in 2026.
• The last three Common Equity figures came in at $2.7 million (Q2 2026), -$1.1 million (Q1 2026), and $895000.0 (Q4 2025), per Business Quant data.